Pay in 4 interest-free payments of $6.46 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Could my medicines, diet, surgery or another condition be contributing
Brigelius-Flohe R
Consistent data collection makes protocol adjustments more informed and outcomes more meaningful
RGN-352 was shown to be safe and well-tolerated with no serious drug-related adverse events reported (PMID: 20536472) Phase 2 AMI trial (incomplete): RegeneRx designed a Phase 2 proof-of-concept trial (NCT01311518) to evaluate RGN-352 in approximately 75 patients with acute ST-segment elevation myocardial infarction (heart attack)
US$ 22.08
US$ 26.52
US$ 27.22
US$ 22.55
US$ 26.46
US$ 24.92
